Sustained Efficacy and Comparable Safety and Immunogenicity after Transition to SB5 (an Adalimumab Biosimilar) Vs. Continuation of SB5 or Reference Adalimumab (Humira®) in Patients with Rheumatoid Arthritis: Results of Phase III Study by Weinblat, M. et al.
Date: Sunday, November 13, 2016
Session Title: Rheumatoid Arthritis – Small
Molecules, Biologics and Gene Therapy -
Poster I
Session Type: ACR Poster Session A
Session Time: 9:00AM-11:00AM
ABSTRACT NUMBER: 604
Sustained E cacy and Comparable Safety and
Immunogenicity after Transition to SB5 (an Adalimumab
Biosimilar) Vs. Continuation of SB5 or Reference
Adalimumab (Humira®) in Patients with Rheumatoid
Arthritis: Results of Phase III Study
Michael Weinblatt , Asta Baranauskaite , Jaroslaw Niebrzydowski , Eva Dokoupilova , Agnieszka
Zielinska , Karina Sitek-Ziolkowska , Janusz Jaworski , Artur Racewicz , Margarita Pileckyte , Krystyna
Jedrychowicz-Rosiak , Vyacheslav Zhdan , Soo Yeon Cheong  and Jeehoon Ghil , Brigham and
Women’s Hospital, Boston, MA, Lithuanian University of Health Sciences, Kaunas, Lithuania, Medica
Pro Familia, Gdynia, Poland, MEDICAL PLUS s.r.o, Uherske Hradiste, Czech Republic, Medica Pro
Familia Sp. z o.o. Spolka Komandytowo-Akcyjna, Warszawa, Poland, Medica pro Familia, Katowice,
Poland, Reumatika Centrum Reumatologi, Warszawa, Poland, Zdrowie Osteo- Medic s.c, Bialystok,
Poland, Przychodnia Neuromedyka, Zyrardów, Poland, M.V.Sklifosovskyi Poltava Regional Clinical
Hospital, Poltava, Ukraine, Samsung Bioepis Co., Ltd., Incheon, South Korea
Meeting: 2016 ACR/ARHP Annual Meeting
Date of  rst publication: September 28, 2016
Keywords: biosimilars
SESSION INFORMATION
Background/Purpose: SB5 has been developed as a biosimilar of the reference adalimumab (ADL).
The 24-week results of the phase III study have been reported.  E cacy, safety, and immunogenicity
results in the transition period (Week 24 to Week 52) will be presented.
Methods: Patients with RA were randomized in a 1:1 ratio to receive either 40 mg of SB5 or ADL
every other week with background methotrexate. After 24 weeks of treatment, patients in the ADL
group were re-randomized (1:1) to either be transitioned to SB5 (ADL/SB5) or continue on ADL
(ADL/ADL) up to Week 50. Patients receiving SB5 continued to receive SB5 (SB5/SB5) but they
followed the randomization procedure for blinding purposes. E cacy, safety, and immunogenicity
were assessed up to Week 52.
Results: After 24-weeks of treatment, 254 patients from SB5 continued to receive SB5 (SB5/SB5), 125
patients from ADL were transitioned to SB5 (ADL/SB5), and 129 patients from ADL continued to
receive ADL (ADL/ADL). Baseline characteristics at baseline and disease activities at re-randomization
were comparable across treatment groups. The ACR responses were sustained and comparable
across treatment groups during the transition period in the full analysis set (Figure). At Week 52 the
ACR20 response rates were 76.9% vs. 81.1% vs. 71.2% in SB5/SB5, ADL/SB5, and ADL/ADL in the per-
protocol set. Other e cacy endpoints including radiographic change were also comparable across
1 2 3 4
5 6 7 8 2
9 10 11 11 1
2 3
4 5
6
7 8
9 10
11
1
PDFCROWD.COM
the treatment groups. The mean change from baseline in modi ed Total Sharp Score was 0.17 in
SB5/SB5 vs. 0.25 in ADL/SB5 vs. 0.50 in ADL/ADL. The safety pro le during the transition period was
comparable across treatment groups. The proportion of patients with any treatment-emergent
adverse events after transition was 32.3% in SB5/SB5, 37.6% in ADL/SB5, and 33.1% in ADL/ADL and
two patients in ADL/ADL group only newly reported injection site reactions. The incidence of anti-
drug antibody after transition was 15.7% vs. 16.8% vs. 18.3% in SB5/SB5, ADL/SB5, and ADL/ADL,
respectively.
Conclusion: E cacy, safety, and immunogenicity pro les were comparable between SB5/SB5,
ADL/SB5, and ADL/ADL during the transition period (Week 24 to Week 52). There were no treatment
emergent issues or clinically relevant immunogenicity precipitated by switching.   
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